Tags

Type your tag names separated by a space and hit enter

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
Lancet Oncol. 2010 Nov; 11(11):1048-56.LO

Abstract

BACKGROUND

Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer.

METHODS

Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and information about the year of diagnosis. HPV detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions.

FINDINGS

22,661 paraffin-embedded samples were obtained from 14,249 women. 10,575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90-92). HPV types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70-72) of invasive cervical cancer. HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92-96) of cervical adenocarcinomas. Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively).

INTERPRETATION

To our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45.

Authors+Show Affiliations

IDIBELL, Institut Català d'Oncologia-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain. s.sanjose@iconcologia.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20952254

Citation

de Sanjose, Silvia, et al. "Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: a Retrospective Cross-sectional Worldwide Study." The Lancet. Oncology, vol. 11, no. 11, 2010, pp. 1048-56.
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H. R., Vallejos, C. S., de Ruiz, P. A., Lima, M. A., Guimera, N., Clavero, O., Alejo, M., Llombart-Bosch, A., Cheng-Yang, C., Tatti, S. A., ... Bosch, F. X. (2010). Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet. Oncology, 11(11), 1048-56. https://doi.org/10.1016/S1470-2045(10)70230-8
de Sanjose S, et al. Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: a Retrospective Cross-sectional Worldwide Study. Lancet Oncol. 2010;11(11):1048-56. PubMed PMID: 20952254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. AU - de Sanjose,Silvia, AU - Quint,Wim Gv, AU - Alemany,Laia, AU - Geraets,Daan T, AU - Klaustermeier,Jo Ellen, AU - Lloveras,Belen, AU - Tous,Sara, AU - Felix,Ana, AU - Bravo,Luis Eduardo, AU - Shin,Hai-Rim, AU - Vallejos,Carlos S, AU - de Ruiz,Patricia Alonso, AU - Lima,Marcus Aurelho, AU - Guimera,Nuria, AU - Clavero,Omar, AU - Alejo,Maria, AU - Llombart-Bosch,Antonio, AU - Cheng-Yang,Chou, AU - Tatti,Silvio Alejandro, AU - Kasamatsu,Elena, AU - Iljazovic,Ermina, AU - Odida,Michael, AU - Prado,Rodrigo, AU - Seoud,Muhieddine, AU - Grce,Magdalena, AU - Usubutun,Alp, AU - Jain,Asha, AU - Suarez,Gustavo Adolfo Hernandez, AU - Lombardi,Luis Estuardo, AU - Banjo,Aekunbiola, AU - Menéndez,Clara, AU - Domingo,Efrén Javier, AU - Velasco,Julio, AU - Nessa,Ashrafun, AU - Chichareon,Saibua C Bunnag, AU - Qiao,You Lin, AU - Lerma,Enrique, AU - Garland,Suzanne M, AU - Sasagawa,Toshiyuki, AU - Ferrera,Annabelle, AU - Hammouda,Doudja, AU - Mariani,Luciano, AU - Pelayo,Adela, AU - Steiner,Ivo, AU - Oliva,Esther, AU - Meijer,Chris Jlm, AU - Al-Jassar,Waleed Fahad, AU - Cruz,Eugenia, AU - Wright,Thomas C, AU - Puras,Ana, AU - Llave,Cecilia Ladines, AU - Tzardi,Maria, AU - Agorastos,Theodoros, AU - Garcia-Barriola,Victoria, AU - Clavel,Christine, AU - Ordi,Jaume, AU - Andújar,Miguel, AU - Castellsagué,Xavier, AU - Sánchez,Gloria I, AU - Nowakowski,Andrzej Marcin, AU - Bornstein,Jacob, AU - Muñoz,Nubia, AU - Bosch,F Xavier, AU - ,, Y1 - 2010/10/15/ PY - 2010/10/19/entrez PY - 2010/10/19/pubmed PY - 2010/12/14/medline SP - 1048 EP - 56 JF - The Lancet. Oncology JO - Lancet Oncol VL - 11 IS - 11 N2 - BACKGROUND: Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. METHODS: Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and information about the year of diagnosis. HPV detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions. FINDINGS: 22,661 paraffin-embedded samples were obtained from 14,249 women. 10,575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90-92). HPV types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70-72) of invasive cervical cancer. HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92-96) of cervical adenocarcinomas. Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively). INTERPRETATION: To our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45. SN - 1474-5488 UR - https://www.unboundmedicine.com/medline/citation/20952254/Human_papillomavirus_genotype_attribution_in_invasive_cervical_cancer:_a_retrospective_cross_sectional_worldwide_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(10)70230-8 DB - PRIME DP - Unbound Medicine ER -